Navigation Links
Santaris Pharma A/S Advances RNA-Targeted Drug Development Candidate Against PCSK9, an Important New Target for the Treatment of High Cholesterol
Date:4/26/2010

on in managing their cholesterol levels.

"There is a lot of interest in PCSK9 as an exciting new target for the treatment of high cholesterol and having demonstrated that SPC5001 effectively lowers LDL or the 'bad' cholesterol in preclinical studies, we are quickly moving forward with plans to advance SPC5001 into clinical studies as a potential new treatment to help patients better manage the risks of cardiovascular diseases," said Henrik Orum, PhD, Vice President and Chief Scientific Officer of Santaris Pharma A/S. "SPC5001 is a testament to the efficiency of our LNA Drug Platform and Drug Discovery Engine as we discovered, optimized and advanced SPC5001 into preclinical development in just 18 months."

The LNA Drug Platform and Drug Discovery Engine developed by Santaris Pharma A/S combines the Company's proprietary LNA chemistry with its highly specialized and targeted drug development capabilities to rapidly deliver potent single-stranded LNA-based drug candidates for a range of diseases including metabolic disorders, infectious and inflammatory diseases, cancer and rare genetic disorders.

"In addition to advancing SPC5001 into drug development for the treatment of high cholesterol, we remain on track to begin Phase 2 clinical trials of miravirsen (SPC3649) in patients with Hepatitis C in the second half of this year," said Soren Tulstrup, President and Chief Executive Officer, Santaris Pharma A/S. "In our internal programs and partnered programs, the versatility and broad utility of Santaris Pharma A/S LNA Drug Platform and Drug Discovery Engine continues to be critical in developing effective RNA-targeted therapies with high affinity, target specificity and remarkable potency for a range of diseases."

SPC5001 adds to the portfolio of Santaris Pharma A/S drugs in development, including its most advanced c
'/>"/>

SOURCE Santaris Pharma A/S
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008
2. Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule
3. Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark
4. Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009
5. Santaris Pharma A/S Forms Strategic Alliance With Shire plc to Develop RNA-Based Medicines for the Treatment of Rare Genetic Disorders
6. Shire Builds Competitive Position of its HGT Business through Research Collaboration with Santaris Pharma A/S on LNA Drug Platform
7. New Collaborations and Breakthrough Advancements in RNA-Based Drug Development Programs Lead Santaris Pharma A/S to Establish US Operations
8. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
9. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... April 17, 2015  US-Australian drug discovery company, Novogen, ... of Understanding with the Feinstein Institute for Medical ... to collaborate with the objective of ... The collaboration brings together the drug discovery expertise ... of the Feinstein Institute in neurosciences and oncology. ...
(Date:4/16/2015)... (PRWEB) April 17, 2015 Spirax ... system services, released their newly designed, state-of-the-art website ... customer facing website effectively promotes the Spirax Sarco ... All the information that a site visitor might ... services, company capabilities, industries serviced, the latest company ...
(Date:4/16/2015)... Miami, FL (PRWEB) April 16, 2015 ... therapy cap distribution and physician network in Europe ... marketing company has appointed Fernando Bermúdez, former Business ... Director. , An industry veteran, Mr. Bermúdez’s professional ... by 75% in Spain, while also penetrating the ...
(Date:4/16/2015)... Ohio (PRWEB) April 16, 2015 ... Index, overexertion involving an outside source was ranked ... This includes injuries related to lifting, pushing, pulling, ... billion in direct costs. The David Round Company ... is committed to working hard to develop and ...
Breaking Biology Technology:Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 2Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 3Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 4Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 5Novogen and Feinstein Institute Join Forces to Find Effective Treatments for Brain Cancer 6Spirax Sarco website has a new look 2Capillus, LLC Extends Laser Hair Therapy Products to Europe and Asia 2The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2
... France, April 23 , - ... Essilor International, the world leader in ophthalmic optics, today,announced ... 31, 2009, representing a reported 10.3% increase on the first ... the period. , Despite contracting demand ...
... RICHMOND, Calif., April 22 Sangamo BioSciences, Inc. (Nasdaq: ... will release its first quarter 2009 financial results on ... press release will be followed by a conference call ... the public via telephone and webcast. During the conference ...
... to Discuss Results to Be Held at 9:00 A.M. - ... VPHM ) first quarter financial results for 2009 are ... the open of the U.S. financial markets.The company will host ... Eastern Time on the same day. During the conference ...
Cached Biology Technology:Essilor : 2009 First Quarter Report 2Essilor : 2009 First Quarter Report 3Essilor : 2009 First Quarter Report 4Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast 2Sangamo BioSciences Announces First Quarter 2009 Conference Call and Webcast 3ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009 2
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
(Date:3/23/2015)... Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, announces its biometric payment technology, ... on CNBC television starting March 30 th . ... in New York markets. ... are excited about our new ad campaign following the recent ...
(Date:3/20/2015)... , Mar. 19, 2015 Research and Markets ... "Iris Biometrics - Global Strategic Business Report" report ... markets for Iris Biometrics in US$ Thousands. The report provides ... , Japan , Europe ... , and Latin America . ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 2Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 3Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 4Iris Biometrics - Global Strategic Business Report 2015: System & Network Access Control - A Robust Market Opportunity in the Offing 5
... or defeat is influenced by his or her stance ... studies of the most recent presidential and congressional elections. ... whether candidates, statements on climate change translated into real ... political science at Stanford, who led two new studies ...
... ANTONIO, Texas (Oct. 12, 2011) Scientists have sequenced the ... to understanding the animal,s extraordinarily long life and good health. ... The University of Texas Health Science Center at San Antonio ... Nature . "If we understand which genes are different ...
... team of researchers has overcome a major hurdle in ... sieve that could make the production of gasoline, plastics ... The breakthrough research, led by chemical engineering and materials ... Science and Engineering, is published in the most recent ...
Cached Biology News:Stanford researchers examine impact of 'green politics' on recent national elections 2Stanford researchers examine impact of 'green politics' on recent national elections 3Barshop Institute, global team sequences DNA of naked mole rat 2Minnesota discovery could make fuel and plastics production more energy efficient and cost effective 2
Polyethylene Glycol 8000, 1 kg. PEG 8000.Used in differential DNA precipitation. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
... Panomer 9 oligodeoxynucleotides are ... labeled at the 5' ... Alexa Fluor dyes and ... assessing microarray spot morphology, ...
Mycoplasma tested...
The Spheroplast Kit contains qualified reagents for the preparation of yeast spheroplasts. The reagents have been optimized for use with Pichia pastoris and are guaranteed to generate 70% spheroplast...
Biology Products: